What you should know:
1. Takeda was supposed to divest its IBD candidate, SHP 647.
2. Takeda requested to waive the divestment procedure after the development of several circumstances during the divestiture process.
3. The commission reversed its decision because:
New IBD drugs emerged with better safety and efficacy profiles than Takeda and Shire’s candidate
Some studies on SHP 647 yielded negative results
Researchers had issues recruiting patients to trials for SHP 647
4. Takeda and Shire now regained the rights to the drug candidate.
More articles on healthcare:
15 ransomware operators that leak stolen data if they aren’t paid
Former clinic administrator gets 4 years for stealing, selling patient information
Geisinger hospital employee unnecessarily accessed 800 patient records: 4 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.